Overview

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

Status:
Recruiting
Trial end date:
2023-07-02
Target enrollment:
Participant gender:
Summary
THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION
Phase:
Phase 1
Details
Lead Sponsor:
Emalex Biosciences Inc.
Collaborators:
Clario
PPD
Treatments:
Ecopipam
Moxifloxacin